• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Board members include industry leaders, investors

Article

Alimera Sciences Inc. has added two notable names in the ophthalmology industry to its board of directors.

Alimera Sciences Inc. has added two notable names in the ophthalmology industry to its board of directors.

Steve Martin, JD, a former president of CIBA Vision Corp. USA and founder of its optics and ophthalmics business, and Calvin W. Roberts, MD, clinical professor of ophthalmology at Weill Medical College at Cornell University, joined the board in July.

Martin is chief executive officer and partner at Hi Tech Partners in Atlanta, where he advises early-stage technology firms.

They join representatives from each of the four venture capital firms that invested in Alimera Sciences. Intersouth Partners led financing with more than $6 million, an amount matched by BA Venture Partners, Domain Associates, and Polaris Venture Partners.OT

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.